Skip to main content
. 2017 Sep 23;8(52):89970–89977. doi: 10.18632/oncotarget.21205

Table 1. Primers used in the present study.

Molecule Forward Reverse
PCAF cctcttctggacttgaggca tggtctctggtccaagcatt
HAT1 ctacaatgtggcctgcatcc ttgatggtgatctgtggcct
MOZ tgcccaatcctttctaagcc acactacttactgagcgccg
MORF cttaatggactgtggcgtcg ctgctctcctgggtcaaaga
P300 ttgtgaagagccccatggat gctttgcatcactgggtcaa
HBO1 ccacgaactcctcctccatt agtcagggattgtggtgagg
HAT1 gtgtacccagacaaaacccg ccgggaaaaacagggcaaat
SRC-1 ggtaaaaggtgcaggtgtgg acaaagtacggggaaggagg
TAF-1 aagttcctgggcctaactcc ctcttccggatgctgctttc
TIF-2 gttttgccagccacttacca aacacactggcgttttctcc
SRC-3 acatgggagtcctggtcttg ctggaaaagctgtggttccc
GCN5 tccccattgacctgaagacc cctccctccttgagcttgaa
CLOCK gtgttacatcgcgccatcat cattaggagggctgagaggg
Fas cttctggggagtgagggaag cttccccaactccgtactga
PAR2 gcgatcttctgccatggatg gtcgatgcagctgttaaggg